Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Shionogi-ViiV

- PMLiVE

GSK’s Zejula challenges AZ/Merck’s Lynparza in PARP inhibitor category

New data in ovarian cancer creates potential for market battle

- PMLiVE

GSK and Apotex join generic Zantac recalls as carcinogen concerns mount

Novartis’ generic unit Sandoz halted distribution last week

- PMLiVE

GSK to develop Ionis hepatitis B drugs

Competing with rivals Gilead to find cure for 200 million people

- PMLiVE

GSK preps filings for BCMA-targeting multiple myeloma drug

On course to file before end of year

- PMLiVE

Pfizer goes big on gene therapy with $500m facility spend

Continues to build on its growing gene therapy business

- PMLiVE

GSK files anaemia drug daprodustat in Japan, its first market

Around 3.5 million people in Japan could access the drug

- PMLiVE

GSK hires Merck KGaA exec to lead US pharma business

Martinez-Davis will help strengthen company’s oncology focus

- PMLiVE

Sarepta investigating mistakenly submitted Duchenne therapy report

Study participant fell seriously ill

- PMLiVE

Pfizer set to unveil Mylan merger and spin-off

Follows consumer health deal with GSK

- PMLiVE

Hal Barron touts new drive to improve GSK’s research output

'Consensus-led' research being replaced with bold decision-making

- PMLiVE

ViiV builds case for switching to its two-drug HIV combinations

Taking aim at rival Biktarvy

- PMLiVE

AstraZenca to appeal NICE rejection of Tagrisso

Pfizer’s Vizimpro wins recommendation

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links